Mepolizumab for chronic rhinosinusitis with nasal polyps ( SYNAPSE ): In‐depth sinus surgery analysis
Allergy · 2023-03 · 78 (3) · 812-821
DOI: 10.1111/all.15434 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Allergy, online erschienen am 27.07.2022. Verfasst von Wytske J Fokkens und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, University of Amsterdam, Amsterdam, Netherlands. Hauptthemen laut MEDLINE: Nasal Polyps, Sinusitis, Rhinitis. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: GlaxoSmithKline.
Abstract (Originalsprache)
Background
Patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) often require repeat sinus surgery. Mepolizumab reduced the need for sinus surgery in the SYNAPSE trial; this analysis sought to provide a more in‐depth assessment of surgery endpoints in SYNAPSE.
Methods
SYNAPSE was a double‐blind Phase III trial (NCT03085797) in adults with recurrent, refractory, severe, CRSwNP eligible for repeat sinus surgery despite standard of care treatments and previous surgery. Patients were randomized (1:1) to mepolizumab 100 mg subcutaneously or placebo, plus standard of care, every 4 weeks for 52 weeks. Time to first inclusion on a waiting list for sinus surgery and time to first actual sinus surgery (both up to week 52) were assessed; the latter endpoint was also analyzed post hoc according to time since last sinus surgery before study screening and baseline blood eosinophil count.
Results
Among 407 patients (mepolizumab: 206; placebo: 201), mepolizumab versus placebo reduced the risk of being included on a waiting list for sinus surgery (week 52 Kaplan–Meier probability estimate [95% confidence interval]: 13.9% [9.8%, 19.5%] vs. 28.5% [22.7%, 35.4%]). Mepolizumab versus placebo reduced the risk of sinus surgery irrespective of time (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology, University of Amsterdam, Amsterdam, Netherlands.
- Department of Otorhinolaryngology, Hospital Clinic, IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain.
- Department of Otorhinolaryngology: Head and Neck Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Norwich Medical School, University of East Anglia, Norwich, UK.
- Norfolk and Waveney Ear Nose and Throat Service, James Paget University Hospitals NHS Foundation Trust, Great Yarmouth, UK.
- ENT Unit, Department of Neuroscience, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
ORCID-Profile: Wytske J Fokkens, Carl Philpott, Peter H Howarth
Förderung
- GlaxoSmithKline
Zitieren
APA
Fokkens, W. J., Mullol, J., Kennedy, D., Philpott, C., Seccia, V., Kern, R. C., Coste, A., Sousa, A. R., Howarth, P. H., Benson, V. S., Mayer, B., Yancey, S. W., Chan, R., & Gane, S. B. (2023). Mepolizumab for chronic rhinosinusitis with nasal polyps ( SYNAPSE ): In‐depth sinus surgery analysis. Allergy, 78(3), 812-821. https://doi.org/10.1111/all.15434
Vancouver
Fokkens WJ, Mullol J, Kennedy D, Philpott C, Seccia V, Kern RC, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps ( SYNAPSE ): In‐depth sinus surgery analysis. Allergy. 2023;78(3):812-821. doi:10.1111/all.15434
BibTeX
@article{Fokkens2023,
author = {Fokkens, Wytske J and Mullol, Joaquim and Kennedy, David and Philpott, Carl and Seccia, Veronica and Kern, Robert C and Coste, André and Sousa, Ana R and Howarth, Peter H and Benson, Victoria S and Mayer, Bhabita and Yancey, Steve W and Chan, Robert and Gane, Simon B},
title = {Mepolizumab for chronic rhinosinusitis with nasal polyps ( SYNAPSE ): In‐depth sinus surgery analysis},
journal = {Allergy},
year = {2023},
volume = {78},
number = {3},
pages = {812--821},
doi = {10.1111/all.15434}
}
EUVIMED